Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112257 | 0.92 | GHSR (0.63) | GHSR | |
| SCHEMBL3671187 | 0.92 | GHSR (0.79) | GHSR | |
| SCHEMBL3671185 | 0.92 | GHSR (0.79) | GHSR | |
| SCHEMBL3665302 | 0.89 | GHSR (0.81) | GHSR | |
| SCHEMBL3665303 | 0.89 | GHSR (0.81) | GHSR | |
| SCHEMBL13693719 | 0.87 | GHSR (0.55) | GHSR | |
| SCHEMBL3632427 | 0.86 | GHSR (0.78) | GHSR | |
| SCHEMBL3632429 | 0.86 | GHSR (0.78) | GHSR | |
| SCHEMBL4100724 | 0.85 | GHSR (0.70) | GHSR | |
| SCHEMBL3679185 | 0.85 | GHSR (0.82) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265593-B1 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF | AETERNA ZENTARIS GMBH (DE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2604594-A1 | 1,2,4-Triazole derivatives as ghrelin analogue ligands of GHS receptors | Æterna Zentaris GmbH (DE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2604594-A1 | 1,2,4-Triazole derivatives as ghrelin analogue ligands of GHS receptors | Æterna Zentaris GmbH (DE) | 2013-06-19 | — | — | EP | disclosed |
| WO-2009115503-A1 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239877-A1 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF | AETERNA ZENTARIS GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090239877-A1 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF | AETERNA ZENTARIS GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| US-20090239877-A1 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF | AETERNA ZENTARIS GMBH (DE) | 2009-09-24 | — | — | US | disclosed |
| EP-2103602-A1 | Novel 1,2,4-triazole derivatives and process of manufacturing thereof | AEterna Zentaris GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239877-A1 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF | CYP3A4, CYP4B1, CYP1B1 | GHSR 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.